Dr Egil Johnson and colleagues from Norway evaluated self-expandable stents in patients with malignant esophageal stenosis.
The research team reported on survival and complications after insertion of these self-expandable stents.
Data were gathered retrospectively from the medical records of 92 consecutive patients between 1994 and 2003.
The researchers assessed 68 men and 24 women, with a median age of 72 years.
The team reported that 61 patients had stenosis from cancer of the esophagus, 26 of the gastric cardia, and 5 of the lung.
A further 4 patients had stenosis from cancer located mainly above the carina, 62 below the carina, and 26 at the gastro-esophageal junction.
The researchers noted that 1 uncovered stent and 6 different covered stents were used.
|30-day mortality was 19%, and 7% survived more than 1 year|
|Scandanavian Journal of Gastroenterology|
The mean survival times after stenting was 125 days.
The team found that 30-day mortality was 19%, and 7% survived more than 1 year.
Survival was neither significantly influenced by division of the patients into diagnostic subgroups nor by comparison of the 3 most frequently used stents.
The team noted that 1, 2, 3 and 4 stents were received by 76, 11, 4 and 1 of the patients, respectively.
There was no stent-related mortality.
The team observed that complications included bleeding, and stent migration.
Recurrent stenosis occurred from both tumor overgrowth and ingrowth when using uncovered stents.
The team found that 14% of patients were restented because of recurrent stenosis, including fistula formation to the left main bronchus, and stent migration.
Dr Johnson's team concludes, “Use of self-expandable stents in patients with inoperable malignant esophageal stenosis carried few complications and resulted in relatively long survival in comparison with similar studies.”